Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients
文献类型：期刊论文
| 作者 | Li, Cong1,2,3; Lu, Fangxiao4; Lei, Tao1,2,3; Yu, Haifeng1,2,3; Yang, Haiyan1,2,3 |
| 刊名 | TRANSLATIONAL CANCER RESEARCH
 |
| 出版日期 | 2020-09-01 |
| 卷号 | 9 |
| 关键词 | B-cell lymphoma chemotherapy interstitial pneumonia (IP) risk factor rituximab |
| ISSN号 | 2218-676X |
| DOI | 10.21037/tcr-20-988 |
| 通讯作者 | Yang, Haiyan(yanghy@zjcc.org.cn) |
| 英文摘要 | Background: Interstitial pneumonia (IP) is a common and fatal adverse effect of rituximab-containing immunochemotherapy in lymphoma patients. Following prophylactic treatment with trimethoprimsulfamethoxazole (TMP-SMX), the clinical features, treatment, and risk factors for IP development remain largely undefined. Methods: From April 2015 and April 2018, 294 patients diagnosed with CD20+ B-cell non-Hodgkin lymphoma (NHL) were included in this study. All patients received front-line RCHOP-like chemotherapy and prophylactic treatment of TMP-SMX once daily. We summarized the clinicopathologic characteristics and treatment outcomes of IP in these patients and explored the possible risk factors of IP. Results: The overall incidence of IP was 8.16%. Typical clinical symptoms included fever for 1-3 days in 11 patients, dyspnea in 4 patients, expectoration in 5 patients, and dry cough in 7 patients. A total of 8 patients showed no apparent symptoms. Prior to IP, the median number of chemotherapy cycles was 4. The median time for IP initiation was 63 days, and the median duration of IP treatment was 11 days. All patients recovered from IP after treatment. A total of 6 patients continued to receive chemotherapy without rituximab, and 14 patients received rituximab combined with chemotherapy. No patients experienced IP recurrence. In univariate and multivariate analysis, male, diabetes, low lymphocyte counts (<1.0x10(9)/L) and low CD4/CD8 counts were identified as risk factors of IP. Patients with no risk factors were included in the low-risk group; 1 to 2 factors: intermediate-risk; >= 3: high-risk. The occurrence of IP differed across three groups (low risk, 0%; intermediate risk, 7%; high risk, 14.5%; P=0.059). Conclusions: The incidence of IP was 8.16% in patients with CD20+ B-cell NHL. Males, diabetes, low absolute lymphocyte counts (ALC) (<1.0x10(9)/L) and low CD4/CD8 were identified as risk factors of IP. |
| WOS关键词 | PNEUMOCYSTIS-JIROVECII PNEUMONIA ; CHEMOTHERAPY PLUS RITUXIMAB ; THERAPY ; CHOP ; CYCLOPHOSPHAMIDE ; SUSCEPTIBILITY ; ADOLESCENTS ; VINCRISTINE ; INFECTIONS |
| 资助项目 | Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2015KYB067] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000575123400003 |
| 出版者 | AME PUBL CO |
| 资助机构 | Medical Health Science and Technology Project of Zhejiang Provincial Health Commission |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/104335]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Yang, Haiyan |
| 作者单位 | 1.Univ Chinese Acad Sci, Dept Med Oncol, Canc Hosp, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Dept Med Oncol, 1 East Banshan Rd, Hangzhou, Peoples R China 3.Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 4.Zhejiang Canc Hosp, Dept Med Imaging, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Cong,Lu, Fangxiao,Lei, Tao,et al. Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients[J]. TRANSLATIONAL CANCER RESEARCH,2020,9. |
| APA | Li, Cong,Lu, Fangxiao,Lei, Tao,Yu, Haifeng,&Yang, Haiyan.(2020).Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients.TRANSLATIONAL CANCER RESEARCH,9. |
| MLA | Li, Cong,et al."Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients".TRANSLATIONAL CANCER RESEARCH 9(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。